Treatment with immunotherapy has become ingrained in the standard of care for treating patients with melanoma, but investigators continue to research new combinations and treatment strategies that can improve patients outcomes.
Conferences
Tel Aviv University’s Prof. Carmit Levy receives Young Investigator Award from SMR
Tel Aviv University’s Prof. Carmit Levy received the prestigious Young Investigator Award at the 16th International Congress of the Society for Melanoma Research, held November 20-23 in Salt Lake City, Utah, for her “contributions to melanoma research that significantly exceeded the average for this career stage."
Large SPORE Grant Focuses on Developing Biomarkers to Predict Melanoma Immunotherapy Treatment Outcomes
The National Cancer Center Institute (NCI) has awarded NYU Langone Health a 5-year, $11 million grant to develop better tools to predict which patients with advanced melanoma will benefit from immune checkpoint inhibitors. The Ronald O. Perelman Department of Dermatology and Perlmutter Cancer Center are using the grant for four distinct and promising projects.
Neoadjuvant T-VEC May Reduce Recurrence in Operable Melanoma
Source: OncLive, July 2019 Neoadjuvant treatment with the oncolytic immunotherapeutic agent talimogene laherparepvec (T-VEC; Imlygic) led to significant improvement in 1-year recurrence-free survival (RFS) for patients with resectable advanced melanoma…
Read More